NDC Pharmacologic Class N0000175451 Tumor Necrosis Factor Receptor Blocking Activity [MoA]

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Product Type
0006-4305Renflexis InfliximabInjection, Powder, Lyophilized, For SolutionIntravenousMerck Sharp & Dohme Corp.Human Prescription Drug
0069-0809Inflectra Infliximab-dyybInjection, Powder, Lyophilized, For SolutionIntravenousPfizer Laboratories Div Pfizer IncHuman Prescription Drug
0074-3797Humira AdalimumabInjection, SolutionSubcutaneousAbbvie Inc.Human Prescription Drug
50090-3531Enbrel EtanerceptSolutionSubcutaneousA-s Medication SolutionsHuman Prescription Drug
50474-710Cimzia Certolizumab PegolInjection, SolutionSubcutaneousUcb, Inc.Human Prescription Drug
57894-030Remicade InfliximabInjection, Powder, Lyophilized, For SolutionIntravenousJanssen Biotech, Inc.Human Prescription Drug
57894-070Simponi GolimumabInjection, SolutionSubcutaneousJanssen Biotech, Inc.Human Prescription Drug
57894-071Simponi GolimumabInjection, SolutionSubcutaneousJanssen Biotech, Inc.Human Prescription Drug
57894-350Simponi Aria GolimumabSolutionIntravenousJanssen Biotech, Inc.Human Prescription Drug
58406-435Enbrel EtanerceptSolutionSubcutaneousImmunex CorporationHuman Prescription Drug
58406-445Enbrel EtanerceptSolutionSubcutaneousImmunex CorporationHuman Prescription Drug
58406-446Enbrel EtanerceptSolutionSubcutaneousImmunex CorporationHuman Prescription Drug
58406-455Enbrel EtanerceptSolutionSubcutaneousImmunex CorporationHuman Prescription Drug
58406-456Enbrel EtanerceptSolutionSubcutaneousImmunex CorporationHuman Prescription Drug

There are 14 NDC products with the pharmacologic class Tumor Necrosis Factor Receptor Blocking Activity [MoA].